228 related articles for article (PubMed ID: 25743506)
1. [Two drugs inhibit disease progression. Idiopathic lung fibrosis treatable for the first time].
Einecke D
MMW Fortschr Med; 2015 Feb; 157(2):24-5. PubMed ID: 25743506
[No Abstract] [Full Text] [Related]
2. [Antifibrotic treatment].
von der Beck D; Löh B; Drakopanagiotakis F; Markart P; Günther A
Dtsch Med Wochenschr; 2014 Dec; 139(49):2523-5. PubMed ID: 25423462
[No Abstract] [Full Text] [Related]
3. Hot off the breath: A big step forward for idiopathic pulmonary fibrosis.
Ryerson CJ; Collard HR
Thorax; 2014 Sep; 69(9):791-2. PubMed ID: 24996636
[No Abstract] [Full Text] [Related]
4. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
Rinciog C; Watkins M; Chang S; Maher TM; LeReun C; Esser D; Diamantopoulos A
Pharmacoeconomics; 2017 Apr; 35(4):479-491. PubMed ID: 28039616
[TBL] [Abstract][Full Text] [Related]
5. Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.
Karimi-Shah BA; Chowdhury BA
N Engl J Med; 2015 Mar; 372(13):1189-91. PubMed ID: 25806913
[No Abstract] [Full Text] [Related]
6. Pirfenidone for idiopathic pulmonary fibrosis.
Bouros D
Lancet; 2011 May; 377(9779):1727-9. PubMed ID: 21571363
[No Abstract] [Full Text] [Related]
7. Two therapies now available for idiopathic pulmonary fibrosis.
Morrow T
Manag Care; 2014 Dec; 23(12):47-8. PubMed ID: 25939185
[No Abstract] [Full Text] [Related]
8. Missing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthrough.
Thabut G; Crestani B; Porcher R; Richeldi L
Eur Respir J; 2015 Sep; 46(3):607-14. PubMed ID: 26324692
[No Abstract] [Full Text] [Related]
9. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.
Aono Y; Nakamura Y; Kono M; Nakamura H; Yokomura K; Imokawa S; Toyoshima M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T
Ther Adv Respir Dis; 2020; 14():1753466620953783. PubMed ID: 32928050
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological treatment of idiopathic pulmonary fibrosis: an update.
Spagnolo P; Wells AU; Collard HR
Drug Discov Today; 2015 May; 20(5):514-24. PubMed ID: 25613790
[TBL] [Abstract][Full Text] [Related]
11. [Two new drugs for the treatment of idiopathic lung fibrosis: A new therapeutic era!].
Crestani B
Rev Med Interne; 2015 Nov; 36(11):719-21. PubMed ID: 26065328
[No Abstract] [Full Text] [Related]
12. [Idiopathic pulmonary fibrosis: A new era, new challenges].
Cottin V
Rev Mal Respir; 2014 Sep; 31(7):583-6. PubMed ID: 25239578
[No Abstract] [Full Text] [Related]
13. Guidelines for the medical treatment of idiopathic pulmonary fibrosis.
Xaubet A; Molina-Molina M; Acosta O; Bollo E; Castillo D; Fernández-Fabrellas E; Rodríguez-Portal JA; Valenzuela C; Ancochea J
Arch Bronconeumol; 2017 May; 53(5):263-269. PubMed ID: 28292522
[TBL] [Abstract][Full Text] [Related]
14. Pirfenidone treatment of idiopathic pulmonary fibrosis.
Azuma A
Ther Adv Respir Dis; 2012 Apr; 6(2):107-14. PubMed ID: 22333982
[TBL] [Abstract][Full Text] [Related]
15. Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis.
Sathiyamoorthy G; Sehgal S; Ashton RW
South Med J; 2017 Jun; 110(6):393-398. PubMed ID: 28575896
[TBL] [Abstract][Full Text] [Related]
16. [Novel therapies for idiopathic pulmonary fibrosis].
Wand O; Kremer MR
Harefuah; 2015 Jul; 154(7):446-50, 469, 468. PubMed ID: 26380465
[TBL] [Abstract][Full Text] [Related]
17. Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF.
Milger K; Kneidinger N; Neurohr C; Reichenberger F; Behr J
Eur Respir J; 2015 Oct; 46(4):1217-21. PubMed ID: 26341986
[No Abstract] [Full Text] [Related]
18. NICE guidance on pirfenidone for treating idiopathic pulmonary fibrosis.
Landells LJ; Naidoo B; Robertson J; Clark P
Lancet Respir Med; 2013 May; 1(3):191-2. PubMed ID: 24429121
[No Abstract] [Full Text] [Related]
19. Is pirfenidone effective for idiopathic pulmonary fibrosis?
Jeldres A; Labarca G
Medwave; 2017 Jan; 17(Suppl1):e6843. PubMed ID: 28112713
[TBL] [Abstract][Full Text] [Related]
20. Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis.
Loeh B; Drakopanagiotakis F; Bandelli GP; von der Beck D; Tello S; Cordani E; Rizza E; Barrocu L; Markart P; Seeger W; Guenther A; Albera C
Am J Respir Crit Care Med; 2015 Jan; 191(1):110-3. PubMed ID: 25551350
[No Abstract] [Full Text] [Related]
[Next] [New Search]
